American private equity giants TPG Capital and KKR & Co. Inc. have emerged as the front runners to invest ₹3,500-4,000 crore for acquiring a 20% stake in Piramal Group’s proposed pharmaceutical entity that would combine the group’s pharma businesses.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
